OptiBiotix Health Plc (OPTI) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of OptiBiotix Health Plc stock £0.03, price £0.06, that is 45.5% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range £0.0485 – £0.5700 · the £0.0555 price screens above the £0.0302 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow OptiBiotix Health in your weekly email
Every Wednesday you see whether OptiBiotix Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally.
Show moreShow less
The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits.
Its first-generation products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; and WellBiome a novel in vitro model of the human gut.
In addition, the company offers second-generation solutions, including Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners; and Microbiome Modulators.
Further, it provides CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings.
The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
Stock analysis
OptiBiotix Health Plc (OPTI) currently trades at £0.0555, while our model-based Fair Value estimate is £0.0302, 46% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
OptiBiotix Health Plc reported revenue of £1.2M in FY2025 versus £2.2M in FY2021, a compound −14.8%/yr. Reported net income was −£3.9M in FY2025.
Key figures
Market cap £5.7M Micro · P/S ratio 4.53 · EPS (TTM) £−0.0400 · Return on equity −65.2% · Return on assets (EBIT) −23.4% (5-year average) · Operating margin −111% · Revenue (TTM) £1.3M · Revenue growth (YoY) +21.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −46%, OPTI screens richer than that median.
Fair Value models
Bear£0.0302Fair Value £0.0302Bull£0.0302
Price £0.0555 · Downside -45.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Revenue growth 1 year
+34.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.4%
’12
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−72.9% (2020) → −268.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−46.1% · Above median
Profitability
Return on assets−56.4% · Bottom 25%
Operating margin (12 months)−110.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)21.9% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.92× · Cheapest 25%
P/S (12 months)4.49× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "OptiBiotix Health Plc Fair Value". https://www.fairvalue-calculator.com/stock/OPTI
Frequently asked questions
Is OptiBiotix Health Plc (OPTI) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of £0.0302 versus a price of £0.0555, about 46% lower (overvalued).
What is the fair value of OPTI?
Our model-based fair value for OptiBiotix Health Plc is £0.0302 (as of Nov 4, 2026), built from audited fundamentals. The current price: £0.0555.
What is the quality score of OPTI?
OptiBiotix Health Plc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OptiBiotix Health Plc (OPTI)?
Our model-based price target is the fair value of £0.0302 (as of Nov 4, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the OptiBiotix Health Plc stock forecast for 2026?
Our models put fair value at £0.0302, about 46% lower versus a price of £0.0555 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of OptiBiotix Health Plc (OPTI)?
OptiBiotix Health Plc reported trailing-twelve-month revenue of about £1.3M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of OptiBiotix Health Plc (OPTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OptiBiotix Health Plc it is £0.0302 per share (as of Nov 4, 2026), against a price of £0.0555. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is OptiBiotix Health Plc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, OPTI trades above its calculated fair value: price £0.0555, fair value £0.0302, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPTI?
No. The price is what the market pays today (£0.0555); the fair value is what the company's own numbers justify (£0.0302). For OptiBiotix Health Plc the two are £0.0253 per share apart. That gap is exactly why we show both numbers side by side.
How much is OptiBiotix Health Plc worth?
The market values OptiBiotix Health Plc at about £5.7M (market capitalisation, as of Nov 4, 2026). Per share that is £0.0555; our models calculate a fair value of £0.0302 per share.
How solid is the balance sheet of OptiBiotix Health Plc (OPTI)?
Balance-sheet figures for OptiBiotix Health Plc (as of Nov 4, 2026): return on equity −65.2%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is OPTI from its 52-week high?
OptiBiotix Health Plc trades at £0.0555, about 34% below its 52-week high of £0.0835 and 14% above the low of £0.0485 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0302 is for.
Which stocks are comparable to OptiBiotix Health Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OptiBiotix Health Plc stock attractive at the current price?
The data as of Nov 4, 2026: price £0.0555, calculated fair value £0.0302 (−46%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPTI calculated?
We run OptiBiotix Health Plc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of £0.0302 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. OptiBiotix Health Plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OptiBiotix Health Plc (OPTI)?
The closing price on Nov 9, 2026 was £0.0555. Our model-based fair value is £0.0302, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OptiBiotix Health Plc right now?
The price sits above even our optimistic bull case (£0.0302). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of OptiBiotix Health Plc
How large is the market capitalisation of OptiBiotix Health Plc (OPTI)?
The market capitalisation of OptiBiotix Health Plc is £5.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OptiBiotix Health Plc (OPTI)?
The price-to-sales ratio of OptiBiotix Health Plc is 4.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OptiBiotix Health Plc (OPTI)?
Earnings per share at OptiBiotix Health Plc are £−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of OptiBiotix Health Plc (OPTI)?
The return on equity (ROE) of OptiBiotix Health Plc is −65.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OptiBiotix Health Plc (OPTI)?
On an EBIT basis the return on assets of OptiBiotix Health Plc is −23.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OptiBiotix Health Plc (OPTI)?
The operating margin of OptiBiotix Health Plc is −111% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OptiBiotix Health Plc (OPTI)?
Revenue at OptiBiotix Health Plc is growing +21.9% versus a year earlier (3y avg +36.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OptiBiotix Health Plc (OPTI)?
Earnings per share at OptiBiotix Health Plc are growing −1.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does OptiBiotix Health Plc (OPTI) generate?
The free cash flow of OptiBiotix Health Plc is −£1.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OptiBiotix Health Plc (OPTI) hold?
OptiBiotix Health Plc holds more cash than debt, £1.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch OptiBiotix Health Plc in the live analysis
One click puts OptiBiotix Health Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
